PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 12, 2020 / 07:40PM GMT
Release Date Price: €44.6 (+3.72%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good afternoon, everyone. Thanks for joining us at the Bank of America Healthcare Conference. Of course, I am Tazeen Ahmad. I am one of the senior biotech analysts at the firm. It's my pleasure to have our next presenting company, PTC Therapeutics.

Speaking for PTC this afternoon are several members from the management team, Chief Executive, Stu Peltz; Chief Financial Officer, Emily Hill; as well as Chief Development Officer, Matt Klein. Thanks, guys, for joining us. Good afternoon.

Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director

Thanks for having us.

Emily Luisa Hill
PTC Therapeutics, Inc. - CFO & Treasurer

Thanks, Tazeen.

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

So maybe, Stu, we could start with a brief intro of the company, maybe a couple of minutes for anyone on the line who may not be as familiar with your story. Just talk about what PTC does.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot